NeuroSense Therapeutics Ltd. Profile

Industry

Biotechnology

Sector

Healthcare

Number of Employees

NeuroSense rapeutics Ltd.'s Business Model

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

About NeuroSense rapeutics Ltd.

Website: https://www.neurosense-tx.com

CEO (Chief Executive Officer): Mr. Alon Ben-Noon

IPO date: 2021-12-09

Contact

Country: IL

Address: Building B

City: Herzliya

State: None

Phone: 972 9 799 6183

Zip Code: 4672562

Other

CIK: 0001875091

ISIN: IL0011809592

CUSIP: M74240108

Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.